Curriculum Vitae

ASSOCIATE PROF. DR. WAN ZAMANIAH BINTI WAN ISHAK @ WAN MOHAMMAD

Associate Professor
  • Department of Oncology Clinical
    Faculty of Medicine
  • zamachi
  • 0379492495

BIOGRAPHY

Associate Prof. Dr. Wan Zamaniah is a Consultant Clinical Oncologist at the University Malaya Medical Centre and University Malaya Specialist Centre, Kuala Lumpur, Malaysia. She graduated from University of Malaya, Kuala Lumpur Malaysia with Bachelor of Medicine & Bachelor of Surgery in 2001. Upon completion of her specialist training in clinical oncology in 2010 at the University of Malaya she joined University Malaya as a lecturer. She is a supervisor and coordinator for Master of Clinical Oncology programme as well as the University Malaya Medical programme at the Faculty of Medicine, UM. She is also actively doing research in clinical oncology field. She is also a council member of Malaysian Oncological Society, an Asia Pacific Regional council member for American Society of Clinical Oncology, a member of Academy of Medicine Malaysia, European Society for Medical Oncology and member of European Society of Radiation Oncology. Her areas of special interest include gastrointestinal cancers, head and neck cancers, gynaecological cancers and thyroid cancer. She is principle investigator for several international clinical trials mainly in gastrointestinal cancers and head and neck cancers. She published some of her works in the areas involved. She speaks in her areas of interest in both local and international scientific conferences.



AREAS OF EXPERTISE

  • ONCOLOGY
    Systemic Cancer Treatment, Radiation Therapy, Cancer Palliative Care

ACADEMIC QUALIFICATION

  • MClinOnc, (Onkology Clinical)
    Universiti Malaya (UM)
  • MBBS, (Medicine and Surgery)
    Universiti Malaya (UM)

ADMINISTRATIVE DUTIES

  • Head of Department
    01 Jan 2024 - present (Clinical Oncology Unit, Faculty of Medicine)
  • CSTRO, CACA, CSCO and ASTRO Joint NPC Contouring Guideline
    06 Nov 2024 - 31 Dec 2024 (International)
  • Clinical Manager
    23 Dec 2010 - present (Department of Oncology, Faculty of Medicine)
  • Coordinator
    07 Jul 2022 - 30 Jun 2024 (Department of Oncology, Faculty of Medicine)
  • Course Coordinator
    24 Sep 2023 - 24 Sep 2023 (Department)
  • Task Force Member
    07 Aug 2023 - 07 Aug 2023 (National)
  • Task Force Member
    13 Jun 2023 - 15 Jun 2023 (University Malaya)
  • Committee Members
    02 Mar 2023 - 07 Apr 2023 (National)
  • Task Force Leader
    15 Dec 2022 - 28 Feb 2023 (National)
  • Committee Members
    17 Jul 2017 - 31 Dec 2022 (National)
  • Task Force Member
    04 Jul 2022 - 30 Sep 2022 (Department)
  • Coordinator
    01 Jun 2020 - 30 Jun 2022 (Department of Oncology, Faculty of Medicine)
  • Ahli Jawatankuasa Penilai Dana Penyelidikan Kementerian Pengajian Tinggi (KPT) 2020 - 2021
    01 Mar 2020 - 31 Dec 2021 (National)
  • Coordinator
    01 Apr 2014 - 31 Mar 2021 (Department of Oncology, Faculty of Medicine)
  • Ahli Jawatankuasa Penyediaan Kertas Soalan Onkologi Klinikal Bagi Peperiksaan MEDEX 2020
    01 Jan 2020 - 31 Dec 2020 (National)
  • Coordinator
    10 Aug 2018 - 09 Aug 2020 (Department of Oncology, Faculty of Medicine)
  • Panel Penemuduga Bagi Kemasukan Ke Program Pengajian Peringkat Ijazah Sarjana Muda Ambilan Sesi Akademik 2020/2021
    02 Jun 2020 - 30 Jun 2020 (University Malaya)
  • Internal Examiner of Master in Clinical Oncology part 2, April 2020
    31 Mar 2020 - 24 Apr 2020 (Faculty)
  • Internal Examiner for Part 1 MCO Exam April 2020
    01 Apr 2020 - 21 Apr 2020 (Department of Oncology, Faculty of Medicine)
  • Coordinator
    01 Apr 2016 - 31 Mar 2020 (Department of Oncology, Faculty of Medicine)
  • Head of Department
    01 Sep 2017 - 01 Sep 2017 (Clinical Oncology Unit, Faculty of Medicine)
  • Coordinator
    01 Sep 2014 - 31 Aug 2016 (Department of Oncology, Faculty of Medicine)
  • Project Coordinator
    07 Nov 2013 - 06 Nov 2014 (Department of Oncology, Faculty of Medicine)
  • Co-supervisor
    07 Oct 2013 - 11 Oct 2013 (Department of Oncology, Faculty of Medicine)
  • Committee member JPPGP
    01 Oct 2013 - 31 Jul 2013 (Department of Oncology, Faculty of Medicine)
  • Departmental E-Learning Co-ordinator
    01 Jun 2012 - 31 May 2013 (Department of Oncology, Faculty of Medicine)

MEMBERSHIPS

  • MALAYSIAN ONCOLOGICAL SOCIETY, COMMITTEE MEMBER
    Since 2013 (National)
  • FULL MEMBER, MEMBER
    2022 to 2023 (International)
  • 20 TECHNICAL COMMITTEE MEMBERS, COMMITTEE MEMBER
    2021 to 2023 (National)
  • AMERICAN SOCIETY OF CLINICAL ONCOLOGY, MEMBER
    2015 to 2023 (International)
  • INTERNATIONAL CORRESPONDING MEMBER, MEMBER
    2015 to 2023 (International)
  • EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY, MEMBER
    2019 to 2022 (International)
  • ESTRO MEMBERSHIP, MEMBER
    2021 to 2021 (International)
  • ESTRO, ACTIVE MEMBER
    2020 to 2020 (International)
  • ASCO, ACTIVE MEMBER
    2018 to 2020 (International)

AWARD AND STEWARDSHIP

  • CERTIFICATE OF EXCELLENT SERVICE
    University of Malaya, 2019 (University)
  • CERTIFICATE OF EXCELLENT SERVICE
    University of Malaya, 2018 (University)
  • EXCELLENCE SERVICE AWARD
    University of Malaya, 2014 (University)
  • Mardi-Maeps TRAIL Explore RUN
    Mardi-MAEPS, 2013 (Community)
  • XTERRA MALAYSIA TRAIL RUN 5.5km 2013
    XTERRA MALAYSIA, 2013 (National)

PUBLICATIONS

Article in Journal
WoS
  1. Shitara, K.; Fleitas, T.; Kawakami, H.; Curigliano, G.; Narita, Y.; Wang, F.; Wardhani, S. O.; Basade, M.; Rha, S. Y.; Zamaniah, W. I. Wan; Sacdalan, D. L.; Ng, M.; Yeh, K. H.; Sunpaweravong, P.; Sirachainan, E.; Chen, M. -h.; Yong, W. P.; Peneyra, J. L.; Ibtisam, M. N.; Lee, K. -w.; Krishna, V.; Pribadi, R. R.; Li, J.; Lui, A.; Yoshino, T.; Baba, E.; Nakayama, I.; Pentheroudakis, G.; Shoji, H.; Cervantes, A.; Ishioka, C.; Smyth, E. (2024). Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer, ESMO OPEN. 9(2). doi:10.1016/j.esmoop.2023.102226
  2. Harrington, Kevin J.; Burtness, Barbara; Greil, Richard; Soulieres, Denis; Tahara, Makoto; de Castro Jr, Gilberto; Psyrri, Amanda; Brana, Irene; Baste, Neus; Neupane, Prakash; Bratland, Ase; Fuereder, Thorsten; Hughes, Brett G. M.; Mesia, Ricard; Ngamphaiboon, Nuttapong; Rordorf, Tamara; Wan Ishak, Wan Zamaniah; Lin, Jianxin; Gumuscu, Burak; Swaby, Ramona F.; Rischin, Danny (2023). Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study, JOURNAL OF CLINICAL ONCOLOGY. 41(4), 790-+. doi:10.1200/JCO.21.02508
  3. Satar, Nur Fadhlina Abdul; Hadi, Yusra; Wee, David Lee Dai; Shariff, Nisha Mohd; Ishak, Wan Zamaniah Wan (2023). Outcome for recurrent nasopharyngeal carcinoma in Malaysia: University Malaya Medical Centre, 2010-2019, ANNALS OF ONCOLOGY. 34, S1424-S1424. doi:10.1016/j.annonc.2023.09.265
  4. Burtness, Barbara; Rischin, Danny; Greil, Richard; Soulieres, Denis; Tahara, Makoto; de Castro Jr, Gilberto; Psyrri, Amanda; Brana, Irene; Baste, Neus; Neupane, Prakash; Bratland, Ase; Fuereder, Thorsten; Hughes, Brett G. M.; Mesia, Ricard; Ngamphaiboon, Nuttapong; Rordorf, Tamara; Wan Ishak, Wan Zamaniah; Ge, Joy; Swaby, Ramona F.; Gumuscu, Burak; Harrington, Kevin (2022). Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score, JOURNAL OF CLINICAL ONCOLOGY. 40(21), 2321-+. doi:10.1200/JCO.21.02198
  5. Chung, Hyun Cheol; Kang, Yoon-Koo; Chen, Zhendong; Bai, Yuxian; Ishak, Wan Zamaniah Wan; Shim, Byoung Yong; Park, Young Lee; Koo, Dong-Hoe; Lu, Jianwei; Xu, Jianming; Chon, Hong Jae; Bai, Li-Yuan; Zeng, Shan; Yuan, Ying; Chen, Yen-Yang; Gu, Kangsheng; Zhong, Wen Yan; Kuang, Shu; Shih, Chie-Schin; Qin, Shu-Kui (2022). Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients, CANCER. . doi:10.1002/cncr.34019
  6. Rischin, Danny; Harrington, Kevin J.; Greil, Richard; Soulieres, Denis; Tahara, Makoto; de Castro Jr, Gilberto; Psyrri, Amanda; Brana, Irene; Neupane, Prakash; Bratland, Ase; Fuereder, Thorsten; Hughes, Brett G. M.; Mesia, Ricard; Ngamphaiboon, Nuttapong; Rordorf, Tamara; Ishak, Wan Zamaniah Wan; Hong, Ruey-Long; Mendoza, Rene Gonzalez; Jia, Liyi; Chirovsky, Diana; Norquist, Josephine; Jin, Fan; Burtness, Barbara (2022).

    Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048

    , ORAL ONCOLOGY. 128. doi:10.1016/j.oraloncology.2022.105815
  7. Keam, B.; Machiels, J-P; Kim, H. R.; Licitra, L.; Golusinski, W.; Gregoire, V; Lee, Y. G.; Belka, C.; Guo, Y.; Rajappa, S. J.; Tahara, M.; Azrif, M.; Ang, M. K.; Yang, M-H; Wang, C-H; Ng, Q. S.; Zamaniah, W. I. Wan; Kiyota, N.; Babu, S.; Yang, K.; Curigliano, G.; Peters, S.; Kim, T. W.; Yoshino, T.; Pentheroudakis, G. (2021). Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck, ESMO OPEN. 6(6). doi:10.1016/j.esmoop.2021.100309
  8. Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., de Castro, G., . . . Investigators, K.-. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, 394(10212), 1915-1928. doi:10.1016/s0140-6736(19)32591-7
  9. Muro, K., Lordick, F., Tsushima, T., Pentheroudakis, G., Baba, E., Lu, Z., . . . Douillard, J. Y. (2019). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncology, 30(1), 34-43. doi:10.1093/annonc/mdy498
  10. Muro, K., Van Cutsem, E., Narita, Y., Pentheroudakis, G., Baba, E., Li, J., . . . Douillard, J. Y. (2019). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncology, 30(1), 19-33. doi:10.1093/annonc/mdy502
  11. Rejab, M.; Wong, J. H. D.; Jamalludin, Z.; Jong, W. L.; Malik, R. A.; Ishak, W. Z. Wan; Ung, N. M. (2018). Dosimetric characterisation of the optically-stimulated luminescence dosimeter in cobalt-60 high dose rate brachytherapy system, AUSTRALASIAN PHYSICAL & ENGINEERING SCIENCES IN MEDICINE. 41(2), 475-485. doi:10.1007/s13246-018-0647-6
  12. Jong, W. L.; Ung, N. M.; Wong, J. H. D.; Ng, K. H.; Ishak, W. Z. Wan; Malik, R. Abdul; Phua, V. C. E.; Cutajar, D. L.; Metcalfe, P. E.; Rosenfeld, A. B.; Ho, G. F. (2016). In vivo skin dose measurement using MOSkin detectors in tangential breast radiotherapy, PHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS. 32(11), 1466-1474. doi:10.1016/j.ejmp.2016.10.022
  13. Zamaniah, W. I. W., Mastura, M. Y., Phua, C. E., Adlinda, A., Marniza, S., Rozita, A. M. (2014). Definitive Concurrent Chemoradiotherapy in Cervical Cancer - a University of Malaya Medical Centre Experience, Asian Pacific Journal of Cancer Prevention. 15(20), 8987-8992
Others
  1. Kong YC, Wong LP, Ng CW, Taib NA, Bhoo-Pathy NT, Yusof MM, Aziz AF, Yehgambaram P, Ishak WZW, Yip CH, Bhoo-Pathy N. Understanding the Financial Needs Following Diagnosis of Breast Cancer in a Setting with Universal Health Coverage.Oncologist. 2020 Jan 10. doi: 10.1634/theoncologist.2019-0426.
  2. Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Souli res, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Neus Bast , Prakash Neupane, se Bratland, Thorsten Fuereder, Brett G M Hughes, Ricard Mes a, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Ruey-Long Hong, Ren Gonz lez Mendoza, Ananya Roy, Yayan Zhang, Burak Gumuscu, Jonathan D Cheng, Fan Jin, Danny Rischin, on behalf of the KEYNOTE-048 Investigators*
  3. Eznal Izwadi Bin Mohd Mahidin, Wan Zamaniah Binti Wan Ishak (2019). Chemotherapy Induced Nausea and Vomiting and Quality of Life of Patients On Moderate And Highly Emetogenic Chemotherapy. Annals of Oncology, Volume 30, Issue Supplement_6, October 2019, mdz343.046
  4. Nisha Shariff, Wan Zamaniah Binti Wan Ishak. Sequential Anthracycline-Taxane Chemotherapy in Node-positive Breast Cancer Amongst Asian Patients - Real-world Outcomes. Annals of Oncology, Volume 30, Issue Supplement_6, October 2019, mdz338.050,
  5. Wan Zamaniah. Clinical Research and Trial Infrastructure in South-East Asia (Malaysia). Annals of Oncology, Volume 30, Issue Supplement_6, October 2019, mdz309.002
  6. Idayu Mat Nawi R, Ping Lei Chui, Wan Ishak WZ, Hsein Chan CM (2018). Oral Cryotherapy: Prevention of Oral Mucositis and Pain Among Patients With Colorectal Cancer Undergoing Chemotherapy. Clin J Oncol Nurs. 22(5):555-560.
  7. K. Muro, F. Lordick et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncol 2018.
  8. M.Rejab, J.H.D Wong, et al. Dosimetric characterisation of the optically-stimulated luminescence dosimeter in cobalt-60 high dose rate brachytherapy system. Australas Phys Eng Sci Med. Online publication. DOI 10.1007/s13246-018-0647-6
  9. Malwinder S, Wan Zamaniah WI, Cimmeran K, Phua VCE. Prognostic Factors For Survival In Pancreatic Cancer Patients From University Malaya Medical Centre, Malaysia. JUMMEC 2018:21 (1)
  10. Alexandre Chan, Matin M.A, Wan Zamaniah W.I, Annielyn B., Antonio H.V, Ravindran K. Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement. Journal of Global Oncology. http://jgo.ascopubs.org/
  11. WL Jong, NM Ung, JHD Wong, KH Ng, WZ Wan Ishak, R Abdul Malik, VCE Phua, DL Cutajar, PE Metcalfe, AB Rosenfeld, GF Ho. (2016). In vivo skin dose measurement using MOSkin detectors in tangential breast radiotherapy. Physica Medica: European Journal of Medical Physics, 32(11), 1466-1474.
  12. Astrid Sinarti Hassan, Manimalat Naisker, Khairul Hazdi Yusof, Wan Zamaniah Wan Ishak. Prognostic Factors and the Role of Adjuvant Chemotherapy in Post-curative Surgery for Dukes B and C Colon Cancers and Survival Outcomes: a Malaysian Experience. Asian Pacific Journal of Cancer Prevention 2015 (16),: 2237-2243
  13. Boon Huat Ng, AM Rozita, A Adlinda, Wei Ching Lee, WI Wan Zamaniah. 2015. Extended Field Radiotherapy With or Without Chemotherapy in Patients with Cervical Cancer and Positive Para-Aortic Lymph Nodes: a Single Institution Retrospective Review. Asian Pac J Cancer Prev, 16(9):3827-3833.
  14. Ee Phua, V. C., Wong, W. Q., Tan, P. L., Bustam, A. Z., Saad, M., Alip, A., Wan Ishak, W. Z. 2015. Capecitabine pattern of usage, rate of febrile neutropaenia and treatment related death in asian cancer patients in clinical practice. Asian Pacific Journal of Cancer Prevention
  15. Vincent Chee Ee Phua, Wei Quan Wong, Pei Lin Tan, Anita Zarina Bustam, MARNIZA SAAD, Adlinda Alip, Wan Zamaniah Wan Ishak. Capecitabine Pattern of Usage, Rate of Febrile Neutropaenia and Treatment Related Death in Asian Cancer Patients in Clinical Practice
  16. Yoke Fui Wong, Mastura Md Yusof, Wan Zamaniah Wan Ishak, Adlinda Alip,Vincent Chee Ee Phua Treatment Outcome for Head and Neck Squamous Cell Carcinoma in a Developing Country: University Malaya Medical Centre, Malaysia from 2003-2010 Asian Pac J Cancer Prev 2015, 16(7), 2903-2908
  17. M.Y. Mastura, S. Marniza, W.I. Wan Zamaniah, P. Vincent, A.M. Rozita, A. Adlinda, G.F. Ho. P0140 Second line aflibercept/folfiri chemotherapy in metastatic colorectal cancer in a single institution in a south east asian country: A case series. European Journal of Cancer 05/2014; 50:e48-e49. DOI: 10.1016/j.ejca.2014.03.184
  18. WI Wan Zamaniah, MY Mastura, CE Phua, A Adlinda, S MARNIZA, AM RozitaDefinitive Concurrent Chemoradiotherapy in Cervical Cancer - a University of Malaya Medical Centre Experience. Asian Pac J Cancer Prev, 15 (20), 8987-8992
  19. WI Wan Zamaniah, MY Mastura, CE Phua, A Adlinda, S Marniza, AM Rozita. Definitive Concurrent Chemoradiotherapy in Cervical Cancer - a University of Malaya Medical Centre Experience. Asian Pac J Cancer Prev, 15 (20), 8987-8992
  20. Phua VCE, Loo WH, Yusof M, Ishak WZW, Tho LM, Ung NM 2013. Treatment Outcome for Nasopharyngeal Carcinoma in University Malaya Medical Centre from 2004-2008. Asian Pac J Cancer Prev, 14(8), 4567-4570.
  21. Phua CE, Tan BS, Tan AL, Ng BS, Eng KY, Abdul Malik R, Wan Ishak WZ. Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma: Penang General Hospital Experience
  22. Rozita A.M., Marniza S., Mastura M.Y.1, Wan Zamaniah W.I.,Yip C.H., Taib N.A. 2010. Patterns of breast cancer relapse at University of Malaya Medical Centre. Journal of University Malaya Medical Centre Vol 13(1)
Article in Proceeding
  1. Jamalludin Z, Min UN, Ishak WW, Malik RA. Preliminary experience on the implementation of computed tomography (CT)-based image guided brachytherapy (IGBT) of cervical cancer using high-dose-rate (HDR) Cobalt-60 source in University of Malaya Medical Centre (UMMC). InJournal of Physics: Conference Series 2016 Mar (Vol. 694, No. 1, p. 012016). IOP Publishing.
Other Publications
  1. B. Keam, J.-P. Machiels , H. R. Kim, L. Licitra et al (2021). Pan-Asian adaptation of the EHNS-ESMO ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. - Policy Paper
  2. Muro, K.; Lordick, F.; Tsushima, et al. (2019). Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Annals of Oncology 30(1), 34 -43 https://doi.org/10.1093/annonc/mdy498 - Policy Paper
  3. Teo Yin Keong, Wan Zamaniah. Lenvatinib, In Treating Advanced Malignant Thyroid Tumours, Real Life Experience from University Malaya Medical Centre. Annals of Oncology, Volume 30, Issue Supplement_6, October 2019, mdz343.072, - Extended Abstract

RESEARCH INTEREST

  • Asian multicenter prospective study of circulating TumoR DNASequencINg (A-TRAIN study) (circulating tumour DNA sequencing cervix)

RESEARCH PROJECT

National
  1. 2021 - 2030, Merck Sharp & Dohme (M) Sdn. Bhd.
    A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial (KEYNOTE-587) ( Principal Investigator(PI))
  2. 2021 - 2027, NOVARTIS CORPORATION (M) SDN. BHD.
    A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PREVIOUSLY TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC, RADIO-ACTIVE IODINE RE-FRACTORY BRAFV600E MUTATION-POSITIVE DIFFERENTIATED THYROID CANCER ( Principal Investigator(PI))
  3. 2022 - 2025, BEIGENE LTD.
    A Randomized, Multicenter, Phase 3 Study Of Zanidatamab In Combination With Chemotherapy With Or Without Tislelizumab In Subjects With Her2-Positive Unresectable Locally Advanced Or Metastatic Gastroesophageal Adenocarcinoma (GEA) ( Principal Investigator(PI))
  4. 2020 - 2023, Fundamental Research Grant Scheme (FRGS)
    Designing a post-discharge care framework for supporting patient with cancer ( Consultant)
  5. 2017 - 2022, Merck Sharp & Dohme (M) Sdn. Bhd.
    A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590). ( Principal Investigator(PI))
  6. 2017 - 2021, Merck Sharp & Dohme (M) Sdn. Bhd.
    A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Asian Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-line Theraphy with Platinum and Fluoropyrimidine. ( Principal Investigator(PI))
  7. 2013 - 2019, FF CanVac Pte Ltd
    A Multicentre, Randomized, Open-Label, Phase III Clinical Trial of Gemcitabine and Carboplatin Followed by Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine and Carboplatin as First Line Treatment for Advanced Nasopharyngeal Carcinoma Patients ( Consultant)
  8. 2013 - 2019, NONE
    Observational Prospective Study in Management of 1st line KRAS Wildtype mCRC with Erbitux (Cetuximab)-OPTIM1SE ( Consultant)
  9. 2012 - 2017, Quintiles Janseen Cilaq
    ABI-PRO- 3002 A phase 3, randamized, double-blind,placebo-controlled study of abiraterone acetate)JNJ-212082) plus prednisone in asymtomic ormildly symptomatic patients with metastaticcastration-resistant prostate cancer ( Consultant)
  10. 2013 - 2017, Roche
    YO28322(MetGastric Study) A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy and Safety of Onartuzumab (MetMAb) in Combination with 5-Fluorocil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients with Metastatic HER2-Negative, Met-Positive Gastroesophageal Cancer ( Consultant)
  11. 2016 - 2017, Private Funding
    A Phase III, Randomized, Open-Label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progresses after First-Line Therapy with Platinum and Fluoropyrimidine ( Principal Investigator(PI))
  12. 2012 - 2015, Janssen Cilag (Johnson & Johnson)
    ABI-PRO 3002 : A phase 3, randomized, double-blind, placebo-controlled study of abiraterone acetate (JNJ-212082) plus prednisone in asymptomic or mildly symptomatic patients with metastatic castration-resistant prostate cancer. ( Consultant)
  13. 2012 - 2015, Roche
    B027952 (GATSBY Study) A randomized, multicenter, adaptive phase II/III study to evaluate the efficacy and safety of trastuzumab emtansine (T-DM1) versus taxane (docetaxel or paclitaxel) in patients with previously treated locally advanced or metastatic HER2-positive gastric cancer, including adenocarcinoma of the gastroesophageal function. ( Consultant)
  14. 2012 - 2014, NONE
    A Randomised Multicentre, Adaptive Phase II/III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine 1(T-DM1) versus taxane (Docetaxel or Paclitaxel)in Patients with Previouly Treated Locally Advanced or Metastatic HER2 Positive Gastric Cancer, Including Adenocarcinoma of the Gastroesophageal Junction (GATSBY) ( Consultant)
  15. 2014 - 2014, NONE
    Prognostic Factor for survival of Duke B and Duke C Cancer after curative surgery in UMMC patient cohort ( Co-Researcher)
  16. 2011 - 2013, Janssen Cilag
    An Open Label Study of Abiraterone Acetate in Subjects with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy ( Consultant)
  17. 2011 - 2013, High Impact Research (HIR)
    Lapatinib study Phase II open-labelstudy of preoperativeweeklypac55 litaxel and carboplatinwithlapatinib (Tykerb ) in patientswith ErB2-positive stage I-III Breastc ncer ( Consultant)
  18. 2010 - 2012, Abbott
    Linifanib vs sorafenib for upfront treatment of advanced hepatocellular carcinoma ( Consultant)
  19. 2008 - 2010, Short Term Research Fund (Vote F)(PJP)
    A prospective controlled study on the role of Scalp Hypothermia to prevent chemotherapy-induced Alopecia in patients with breast cancer receiving anthRacycline and taxanE-based chemotherapy. (SHARE Study) ( Consultant)
Private
  1. 2022 - 2027, Merck Sharpe & Dohme (Malaysia) Sdn Bhd
    A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER) ( Principal Investigator(PI))
International
  1. 2022 - 2024, National Cancer Centre Japan
    Asian multicenter prospective study of circulating tumor DNA sequencing: A-TRAIN ( Principal Investigator(PI))
  2. 2021 - 2024
    Asian multicenter prospective study of circulating tumor DNA sequencing: A-TRAIN (NCCH1905), National Cancer Centre, Tokyo ( Co-Researcher)
  3. 2019 - 2023, International Funding
    The Effect Of An Educational Intervention Integrating A Shared-decision Making Tool On The Utilization Pattern Of Trastuzumab Biosimilar In The Treatment Of Her2+ Breast Cancer In Malaysia ( Co-Researcher)
  4. 2020 - 2022, International Funding
    Asian multicenter prospective study of circulating TumoR DNASequencINg (A-TRAIN study) ( Principal Investigator(PI))
  5. 2019 - 2021, MSD LTD
    MK3475-966 Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for FirstLine Advanced and/or Unresectable Biliary Tract Carcinoma (KEYNOTE-966) ( Principal Investigator(PI))
  6. 2018 - 2021, Private Funding
    A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590) ( Principal Investigator(PI))
  7. 2018 - 2021, Private Funding
    A Prospective and Interventional, non-randomized, study to assess safety and efficacy of Dynamic-Electro Enhanced Chemotherapy for head and neck and/or breast cancer in a palliative setting. The D-EECT- HNBC Trial. ( Principal Investigator(PI))
  8. 2010 - 2020, Amgen
    D- CARE A Randomised Double- Blind, Placebo- Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at High Risk of Recurrence ( Consultant)
  9. 2018 - 2020, Private Funding
    A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL) ( Principal Investigator(PI))
  10. 2014 - 2019, Zeria Pharmaceutical Co., Ltd
    Randomized, Double-blind, Placebo-controlled Trial of Z-100 plus Radiation Therapy in Patients with Locally Advanced Cervical Cancer A Phase III trial ( Consultant)
  11. 2016 - 2018, AB Science
    A prospective, multicenter, double-randomised, double blind, 2-parallel groups, phase 3 study to compare as first line therapy efficacy and safety of masitinib in combination wtih gemcitabine, to gemcitabine in combination with placebo, followed as second line treatment by masitinib in combination with FOLFIRI 3 versus placebo in combination with FOLFIRI 3 in the treatment of non resectable locally advanced or metastatic pancreatic cancer ( Consultant)
  12. 2016 - 2017, MSD Global
    A Phase 3 Clinical Trial of Pembrolizumab(MK-3475) in First Line Treatment ofRecurrent/Metastatic Head and Neck Squamous CellCarcinoma ( Principal Investigator(PI))
  13. 2016 - 2017, Private Funding
    A Phase II, Multi-center, Single-Arm, Global Study of MED14736 Monotheraphy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) ( Principal Investigator(PI))
  14. 2016 - 2017, Private Funding
    A Phase II, Randomized, Open-Label, Multi-Center, Global study of MED14736 in combination with Tremelimumab in Patients with Recurrent or Metastaic Squamous Cell Carcinomo of the Head and Neck ( Principal Investigator(PI))
  15. 2012 - 2015, NONE
    A PHASE III PROSPECTIVE, TWO-COHORT NON- RANDOMIZED, MULTICENTER, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2- POSITIVE EARLY BREAST CANCER [SafeHer Study] ( Consultant)
  16. 2014 - 2015, Genetech Inc
    GDC-0068 Study (JAGUAR) A Randomized, Phase II, Placebo-Controlled Study of GDC-0068, An Inhibitor to Akt, In Combination with Fluoropyrimidine plus Oxaliplatin in Patients with Locally Advanced or Mestatatic Gastric or Gastroesophageal Junction Adenocarcinoma ( Principal Investigator(PI))
  17. 2012 - 2014, GENETECH INC
    A Phase II double-blind placebo-controlled randomised study of GDC-0941 or GDC-0980 with fulvestrant versus fulvestrant in metastatic breast cancer patients resistant to aromatase inhibitors. ( Principal Investigator(PI))
  18. 2011 - 2013, AMGEN COOPERATION
    A PHASE 3, MULTICENTRE, RANDOMIZED, OPEN LABEL TRIAL TO EVALUATE THE SURVIVAL BENEFIT OF PANITUMUMAB AND BEST SUPPORTIVE CARE, COMPARED TO BEST SUPPORTIVE CARE ALONE, IN SUBJECT WITH CHEMOREFRACTORY WILD-TYPE KRAS METASTATIC COLORECTAL CANCER ( Principal Investigator(PI))
  19. 2011 - 2013, Psioxus Therapeutic Limited
    MT-102-2001 : (Myotec Study) A multicentre, randomized, double-blind, placebo- controlled, dose-finding phase II clinical study to evaluate the efficacy of two different doses of MT-102 administered over a sixteen week period in subjects with cachexia related to stage III and IV non small-cell lung cancer and colorectal cancer. ( Consultant)
  20. 2011 - 2012, Sanofi-Aventis
    Multicentre, single-arm, open label, clinical trial intended to provide early access to cabazitaxel in patients with metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen and to document safety of cabazitaxel in these patients. ( Consultant)

CONSULTANCY PROJECT

  • Asco Asia Pacific Regional Council., ASCO, MOS
    01 May 2020 - 01 May 2023 (International)
  • External Reviewer Untuk Kajian Teknologi Kesihatan Prophylactic Anticoagulation in Ambulatory Cancer Patients, Ministry of Health
    01 Sep 2020 - 01 Sep 2020 (National)
  • Msd Virtual Msi H Colorectal Carcinoma Eif 5th September 2020 2:00-4:30 Pm, MSD
    01 Sep 2020 - 01 Sep 2020 (International)
  • Advisory Board Meeting On Hepatocellular Carcinoma On 19th September 2020, Eisai malaysia
    01 Sep 2020 - 01 Sep 2020 (National)
  • Visiting Oncology Consultant to Husm Kubang Kerian, Kelantan, HOSPITAL UNIVERSITI SAINS MALAYSIA
    01 Jan 2019 - 01 Jan 2020 (National)
  • Permohonan Penubuhan Lembaga Perubatan Berhubung Rawatan Carbon Iron Radiation Therapy Di Luar Negara (Jepun) Atas Tanggungan Kerajaan Kepada Pesara Perkhidmatan Awam, Kementerian Kesihatan Malaysia (Institut Kanser Negara)
    01 Jan 2020 - 01 Jan 2020 (National)
  • Lenvima Asian Steering Committee, Bangkok, 2020, Eisai (M) Sdn Bhd
    01 Jan 2020 - 01 Jan 2020 (International)
  • Ulasan Pakar Keatas Produk Yang Sedang Dinilai Untuk Pendaftaran Oleh Pihak Berkuasa Kawalan Dadah (Pbkd), Pihak Berkuasa Kawalan Dadah, Kementerian Kesihatan Malaysia
    01 Dec 2016 - 01 Dec 2016 (National)
  • Ulasan Pakar Ke Atas Produk Yang Sedang Dinilau Untuk Pendaftaran Oleh Pihak Berkuasa Kawalan Dadah (Pbkd), Kementerian Kesihatan Malaysia
    01 Dec 2016 - 01 Dec 2016 (National)
  • Ulasan Pakar Tentang Permohonan Indikasi Baru Bagi Produk Yang Telah Berdaftar Dengan Pihak Berkuasa Kawalan Dadah (Pbkd) - Ts-One, Kementerian Kesihatan Malaysia
    01 Dec 2016 - 01 Dec 2016 (National)
  • Ulasan Pakar Tentang Permohonan Indikasi Baru Bagi Produk Yang Telah Didaftarkan Dengan Pihak Berkuasa Kawalan Dadah (Pbkd), Pihak Berkuasa Kawalan Dadah, Kementerian Kesihatan Malaysia
    01 Dec 2016 - 01 Dec 2016 (National)
  • Avastin in Metastatic Colorectal Cancer (McRc) Advisory Board, ROCHE Malaysia
    01 Nov 2016 - 01 Nov 2016 (National)
  • Asia Immuno-Oncology Steering Committee Meeting, Astra Zeneca
    01 Nov 2016 - 01 Nov 2016 (International)
  • Korea Lenvatinib Advisory Board Meeting, Esai Korea LTD
    01 Dec 2015 - 01 Dec 2015 (International)
  • Advisory Board Meeting for Regional Cinv Guideline, Mundipharma
    01 Jan 2014 - 01 Jan 2015 (International)
  • Authors : Jihane Jihane Khaliltitle : Five Years' Experience Treating Locally Advanced Cervical Cancer With Concurrent Chemoradiotherapy: Results from a Single Institution. Journal : Radiation Oncology, Radiation Oncology
    01 Jan 2014 - 01 Jan 2014 (International)
  • Merck Serono Southeast Asia McRc Expert Panel Meeting, Merck Sdn Berhad
    01 Nov 2013 - 01 Nov 2013 (International)
  • Art of Oncology - Colorectal Cancer Meeting 2013, Sanofi Aventis Malaysia Sdn Bhd
    01 Aug 2013 - 01 Aug 2013 (National)

PAPER PRESENTED

INVITED SPEAKER
  1. From global to local: Malaysia s experience in clinical trials in head and neck cancer, Glocal Oral Cancer Forum 2024, Universiti Malaya (International) (25 May 2024 - 26 May 2024)
  2. ESMO Preceptorship in Immuno-Oncology - Head and Neck Cancers, Esmo Asia Immuno-Oncology, European Society of Medical Oncology (International) (30 Nov 2022 - 01 Dec 2022)
  3. Updates on systemic therapy of relapsed/metastatic SCCHN, Annual Scientific Congress of Malaysian Oncological Society, Malaysian Oncological Society (National) (04 Nov 2022 - 06 Nov 2022)
  4. Exploring Ideal Treatment Approach in DTC, Thyroid Cancer Trial Workshop, Eisai Malaysia Sdn Bhd (National) (25 Mar 2022 - 25 Mar 2022)
  5. Recent advances with ICPI: Results in approved/unapproved indication - Head and Neck Cancer, ESMO Virtual Preceptorship on Immuno-Oncology on 22-23 November 2021, European Society of Medical Oncology (International) (22 Nov 2021 - 23 Nov 2021)
  6. Role Of Radiotherapy In Thyroid Tumor, PRE-CONGRESS WORKSHOP 2 EVOLUTION IN MANAGING THYROID TUMOUR: A PARADIGM SHIFT , Academy of Medicine Malaysia, Academy of Medicine Singapore, Hong Kong Academy of Medicine, College of Surgeon Malaysia (National) (26 Aug 2021 - 26 Aug 2021)
  7. Overview of Lenvatinib in Advanced Radioiodine-refractory Thyroid Cancer and real-world clinical experience, ASHNO 2021 Kuala Lumpur, Malaysian Society of Otorhinolaryngologist Head and Neck Surgeon / Chapter of ORL Academy of Medicine., Malaysian Oncological Society (National) (04 Jun 2021 - 04 Jun 2021)
  8. KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). , Best Of Asco Kuala Lumpur 2020, https://www.mci-group.com (International) (05 Dec 2020 - 06 Dec 2020)
  9. Optimizing the management of Nausea & Vomiting, Live With Expert, Covid 19 and Cancer - Optimizing the management of nausea and vomiting, DKSH Malaysia Sdn Bhd (National) (19 May 2020 - 19 May 2020)
  10. DRUG DEVELOPMENT: FROM DISCOVERY TO CLINICAL APPLICATION, JEMPUTAN SEBAGAI PENCERAMAH ' NURSING SEMINAR SESSION 2/2020: ONCOLOGY' PADA 4 & 5 FEBRUARI 2020, Jabatan Kejururawatan Pusat Perubatan Universiti Malaya (University) (04 Feb 2020 - 04 Feb 2020)
  11. Importance of Bone Care in Advanced Cancer Management , National Orthopaedic Oncology Revision Course 2020, National Orthopaedic Society (University) (18 Jan 2020 - 18 Jan 2020)
  12. Importance of Bone Care in Advanced Cancer Management, National Orthopaedic Oncology Revision Course 2020, Orthopaedic Department UM (University) (18 Jan 2020 - 18 Jan 2020)
  13. How Safe Is TECENTRIQ in 2L NSCLC and Beyond?, Tecentric in 2nd Line NSCLC & Alecensa in ALK+ in NSCLC - Case study sharing, Roche Malaysia Sdn Bhd (National) (13 Dec 2019 - 13 Dec 2019)
  14. Radiotherapy in Cervical Cancer with pro and cons of IGBT, 5th Johor Oncology Meeting, Pusat Rawatan Onkologi, Hospital Sultan Ismail, Johor Bahru (National) (06 Sep 2019 - 06 Jun 2019)
  15. Optimizing treatment of metastatic ovarian cancer and cervical cancer with Avastin, 5th Johor Oncology Meeting, Pusat Rawatan Radioterapi, Hospital Sultan Ismail, Johor Bahru (National) (06 Sep 2019 - 06 Sep 2019)
  16. The East Meets the West - From Clinical Trial to Practice, MSD symposium: Current Trends in Immuno-Oncology (CTIO), MSD MALAYSIA SDN BHD (National) (04 Aug 2019 - 04 Aug 2019)
  17. Neoadjuvant in Pancreatic Cancer, 22nd Asian Congress of Surgery, College of Surgeons, Malaysia (International) (02 Aug 2019 - 04 Aug 2019)
  18. Neoadjuvant treatment in oesophagus cancer, 22nd Asian Congress of Surgery, College of Surgeons, Malaysia (International) (02 Aug 2019 - 04 Aug 2019)
  19. Clinical Research & Trial Infrastructure In Malaysia, 2019 the Japanese Society of Medical Oncology Annual Meeting (JSMO2019), Japanese Society of Medical Oncology  (International) (18 Jul 2019 - 20 Jul 2019)
  20. Safety Management of TKI-associated Toxicity in Treatment of Metastatic Differentiated Thyroid Cancer, The Eisai Symposium of Contemporary Oncology (ESCON), Eisai Co Ltd (International) (17 Feb 2017 - 17 Feb 2017)
  21. Review of Recent IO trials, 2016 Mos Annual Scientific Conference, Malaysian Oncological Society (National) (11 Nov 2016 - 13 Nov 2016)
  22. Management of Symptoms & Adverse Events, AP Oncology Supportive Care Summit, MSD Malaysia (International) (23 Jul 2016 - 24 Jul 2016)
  23. Cancer Treatment Modalities, AP Oncology Supportive Care Summit, MSD Malaysia (International) (23 Jul 2016 - 24 Jul 2016)
  24. Changing treatment paradigm in ER+/Her2- Breast Cancer: The role of cell cycle inhibitor, POW WOW, Pfizer Malaysia & Malaysian Oncological Society (National) (21 Nov 2015 - 22 Nov 2015)
  25. CASE STUDY 1: Chemotherapy Induced Nausea & Vomiting, ESMO-MOS Conference, The European Society for Medical Oncology (ESMO) & Malaysian Oncological Society (International) (22 Jan 2015 - 25 Jan 2015)
  26. Oncologist Workshop: Best Practices in CINV Care and Effective CINV Management , MSD A-P Freestanding CINV Supportive Care Summit , Merck Sharpe & Dohme Corp, USA (International) (10 May 2014 - 11 May 2014)
  27. Understanding Cancer, Public Talk to Johnson & Johnson's Staff for Cancer Awareness Event , Johnson & Johnson Malaysia. (Others) (08 Mar 2013 - 08 Mar 2013)
  28. IMPORTANCE OF CLINICAL AND MOLECULAR PROGNOSTIC AND PREDICTIVE MARKERS., ESMO ASIA CME PARTNER CENTRE: COLORECTAL CANCER PROGRAM, EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) (International) (20 Oct 2012 - 20 Oct 2012)
  29. Managing Patient in Cancer Colon, SEMINAR PERAWATAN ONKOLOGI, Unit Perkembangan Kejururawatan Jabatan Kejururawatan, Pusat Perubatan Universiti Malaya  (Others) (05 Sep 2012 - 05 Sep 2012)
EVENT ORGANISER
  1. Scientific Chairperson & expert panel discussion , UMMC Bone Health Workshop 2020, Department of Clinical Oncology, UMMC & Amgen (Malaysia) Co Ltd  (University) (07 Mar 2020 - 07 Mar 2020)
  2. Treatment and side effect management of bone metastases., Oncology Bone Health Workshop 2020, Jabatan Onkologi Klinikal & Amgen Malaysia Sdn Bhd (National) (07 Mar 2020 - 07 Mar 2020)
  3. Organizing Chair Person, Improving Clinical Outcomes in The Management of Colorectal Cancer, Department of Clinical Oncology, Univerisity of Malaya  (National) (29 Mar 2014 - 29 Mar 2014)
POSTER PRESENTER
  1. THE IMPACT OF COVID-19 PANDEMIC ON PSYCHOLOGICAL WELL-BEING OF ONCOLOGY HEALTHCARE PROVIDERS IN MALAYSIA, Japanese Society of Medical Oncology Congress 2024, Japanese Society of Medical Oncology (International) (22 Feb 2024 - 24 Feb 2024)
  2. THE IMPACT OF COVID-19 PANDEMIC ON PSYCHOLOGICAL WELL-BEING OF ONCOLOGY HEALTHCARE PROVIDERS IN MALAYSIA Confirmed Abstract ID: A-0021, 34th Annual COngress of Malaysian Oncological Society 2023, Malaysian Oncological Society 2023 (National) (06 Oct 2023 - 08 Oct 2023)
  3. A Study of PembrolIzumab (MK-3475) Plus Platinum and GEmcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER), NATIONAL CONFERENCE OF CLINICAL RESEARCH 13TH NCCR VIRTUAL, Ministry of Health Malaysia (National) (24 Aug 2023 - 26 Aug 2023)
  4. The Effect of Coronavirus 2019 (Covid-19) pandemic on breast cancer s diagnosis, staging and treatment, Asia Pacific Breast Cancer Summit 2023, Asia Pacific Breast Cancer Summit Committee (International) (04 May 2023 - 06 May 2023)
  5. TREATMENT OUTCOME OF GASTRIC CANCER IN UNIVERSITY MALAYA MEDICAL CENTRE (UMMC), Japanese Society of Medical Oncology Congress 2023, JSMO (International) (16 Mar 2023 - 18 Mar 2023)
  6. THE TREATMENT OF RECURRENCE AND METASTATIC RADIOIODINE (IODINE-131) REFRACTORY DIFFERENTIATED THYROID CARCINOMA WITH LENVATINIB A SINGLE INSTITUTIONAL EXPERIENCE IN MALAYSIA , the 12th Asia & Oceania Thyroid Association Congress , AOTA & Korean Thyroid Association (International) (16 Mar 2017 - 19 Mar 2017)
  7. Outcome of Routine Radioiodine Ablation for Differentiated Thyroid Cancer in an Academic Institution in Kuala Lumpur, Malaysia , 22nd Asia Pacific Cancer Congress, Chinese Anti-Cancer Association (International) (01 Nov 2013 - 02 Nov 2013)
  8. PROSPECTIVE CONTROLLED STUDY ON THE ROLE OF SCALP HYPOTHERMIA TO PREVENT CHEMOTHERAPY-INDUCED ALOPECIA IN PATIENTS WITH BREAST CANCER RECEIVING ANTHRACYCLINE AND TAXANE-BASED CHEMOTHERAPY (SHARE STUDY), ANNUAL SCIENTIFIC CONGRESS OF MALAYSIAN ONCOLOGICAL SOCIETY, MALAYSIAN ONCOLOGICAL SOCIETY (National) (30 Sep 2010 - 30 Oct 2010)
PRESENTER
  1. Radiotherapy Status in Malaysia (Country Presentation), Asean Trainer Training Course On Radiation Treatment, RCA Regional Office, Korea Institute of Radiological & Medical Sciences (International) (05 Dec 2016 - 09 Dec 2016)
  2. Case Study 3: Continuum of care, Art of Oncology Colorectal Cancer Meeting 2013, Sanofi Aventis Malaysia Sdn Bhd (National) (24 Aug 2013 - 25 Aug 2013)
  3. Case Discussion, Connecting The Dots.. A MDT workshop on management of colorectal cancer., Merck Serono Malaysia Sdn Bhd (National) (29 Jun 2013 - 29 Jun 2013)
OTHERS
  1. Introduction to intravenous chemotherapy, Preceptorship Programme For Oncology Nurses from Myanmar, Clinical Oncology Unit, University Malaya Medical Centre. (International) (13 Apr 2015 - 15 Apr 2015)
  2. Xeloda in colorectal and gastric cancer, Xeloda in Breast Cancer, Colorectal and Gastric cancer Preceptorship program, Clinical Oncology Unit, Pusat Perubatan Universiti Malaya & Roche Myanmar (International) (06 Apr 2015 - 08 Apr 2015)
  3. Capecitabine in CCRT Rectal Cancer, Capecitabine in Pancreatic Cancer, Capecitabine Preceptorship Programme, Clinical Oncology Unit, University of Malaya.Roche. (International) (11 Mar 2014 - 15 Mar 2014)
  4. MOODLE SHARING OF BEST PRACTICES RESEARCHING PRACTICE SEMINAR, MOODLE SHARING OF BEST PRACTICES RESEARCHING PRACTICE SEMINAR, ACADEMIC DEVELOPMENT CENTRE UNIVERSITY OF MALAYA (National) (07 Feb 2013 - 07 Feb 2013)

ACADEMIC/PROF. SERVICES

Evaluation
  1. (2024) Panel Penilai Bagi Sesi Pemantauan Laporan Akhir dan Kewangan Bagi Projek Penyelidikan Di Bawah Program Malaysia-France Bilateral Research Collaboration (Match) 2021, International, (External Assessor)
  2. (2024) Article Reviewer, International, (Reviewer)
  3. (2024) Pfizer Conquer Cancer 'Improving Metastatic Breast Cancer (Mbc) Quality of Care and Equity Via Meaningful Capacity Building in South East Asia, International, (Reviewer)
  4. (2023) Review of Manuscript Id Cnr2-23-0561 - "is There Any Difference Between Eastern and Western Clinical Practice Guidelines in Management of Gastric Cancer?", International, (Reviewer)
  5. (2023) Panel Penilai Bagi Sesi Pemantauan Laporan Prestasi dan Kewangan Bagi Projek Penyelidikan Di Bawah Program Malaysia-France Bilateral Research Collaboration (Match) 2021, International, (External Evaluator)
  6. (2023) Internal Examiner for Part 1 Exam May 2023, University, (Internal Examiner)
  7. (2023) Internal Examiner for Medical Statistics Part 1 Paper May 2023, University, (Internal Examiner)
  8. (2023) End of Life Communication: a Malaysian Survey Among Oncology Doctors, University, (Internal Examiner)
  9. (2023) Review On Lysine Malonylation Proteomics Reveals Protein Modification Alteration in The Central Carbon Metabolism Pathway of Oral Squamous Cell Carcinomas, International, (Reviewer)
  10. (2022) Asco Asia Pacific Leadership Development Program, International, (Reviewer)
  11. (2022) Internal Examiner for Part 1 Master Clinical Oncology, National, (Internal Examiner)
  12. (2022) Internal Examiner for Master in Clinical Oncology Part 2 Exam, National, (Internal Examiner)
  13. (2022) Panel Penemuduga Bagi Kemasukan Ke Program Pengajian Peringkat Ijazah Sarjana Muda Ambilan Sesi Akademik 2022/2023, University, (Internal Examiner)
  14. (2022) Review Article On: Laparoscopic Versus Open Lower Mediastinal Lymphadenectomy for Siewert Type Ii/III Adenocarcinoma of Esophagogastric Junction: An Exploratory, Observational, Prospective, Ideal Stage 2b, Cohort Study (The Class-10 Study), International, (Reviewer)
  15. (2022) Ulasan dan Semakan Pelan Mitigasi Projek Penyelidikan Di Bawah Geran Malaysia-France Bilateral Research Collaboration (Macth 2021), National, (External Evaluator)
  16. (2022) Project Title: Ibtraarterial Therapy for Liver Metastases: a Focus On Hepatic Arterial Chemotherapy and Transarterial Chemoembolization, University Malaya Medical Centre Experience, University, (Internal Examiner)
  17. (2022) Panel Penilai Bagi Sesi Pembentangan dan Pemantauan Prestasi & Kewangan Bagi Projek Penyelidikan Di Bawah Program Malaysia-France Bilateral Research Collaboration (Match) 2021, National, (External Evaluator)
  18. (2021) Review of Manuscript Id Bmjopen-2021-056187 for Bmj Open, International, (Reviewer)
  19. (2021) Asco Leadership Development Program Reviewer 2021, International, (Reviewer)
  20. (2021) Panel Penilai Bagi Permohonan Malaysia-France Bilateral Research Collaboration 2021 (Match), National, (Reviewer)
  21. (2021) Umsc Ca.R.E Fund Research Grant 2021 Application, University, (Reviewer)
  22. (2021) Review for Bmj Open Bmjopen-2020-046681, International, (Reviewer)
  23. (2020) MSD EIF MSI_H CRC 5th Sep 2020 , (Advisory Committee)
  24. (2020) MSD Malaysia Head and Neck Cancer Expert Input Forum (EIF) , (Advisory Committee)
  25. (2020) Eisai Advisory Board Meeting On Hepatocellular Carcinom , (Advisory Committee)
  26. (2020) Re-Imagine Healthcare Hackathon , (Advisory Committee)
  27. (2020) Reviewer article for manuscript # bmjopen-2020-042702 entitled "Clinical characteristics and prediction model of long time survival of patients with stage M1 Siewert type II esophagogastric junction adenocarcinoma" for BMJ Open., (Reviewer)
  28. (2020) Lenvima Asian Steering Committee Meeting, ESCON 2020, 21st Feb (Fri), Bangkok , (Advisory Committee)
  29. (2020) Internal Examiner for Master Clinical Oncology - Thesis evaluation & Part 3 examiner, (Internal Examiner)
  30. (2019) PANEL SEMINAR "PROPOSAL DEFENCE" CALON IJAZAH DOKTOR FALSAFAH HUANG ANH TUNG, (Internal Examiner)
  31. (2019) Quality of life outcome of nasopharyngeal carcinoma survivors in Hospital Universiti Kebangsaan Malaysia, (Reviewer)
  32. (2019) 1st Scientific Exchange Meeting on Head and Neck Cancer by Merck , (Advisory Committee)
  33. (2019) Lenvima Asia Steering Committe Meeting 2019, (Advisory Committee)
  34. (2019) CELGENE CEA ADVISORY BOARD MEETING ON PANCREATIC, BREAST AND LUNG CANCERS (CAPaBLe), (Advisory Committee)
Contribution to external organisation
  1. (2024) Servier's Asian Gi (Pancreatic Cancer & Cholangiocarcinoma) Advisory Board, International, (Resource Person)
  2. (2024) Esmo Asia 2024 | Commercial Advisory Board, International, (Expert Advisor)
  3. (2024) Beigene Southeast Asia Gastric Cancer Advisory Board Meeting, International, (Expert Advisor)
  4. (2024) Atlas Head Neck Cancer Group Committee, International, (Resource Person)
  5. (2024) Chairperson for Pfizer Conquer Cancer Grant Commitee, International, (Expert Advisor)
  6. (2024) Asco International Cancer Corp Group, International, (Resource Person)
  7. (2024) Atlas Board, International, (Expert Advisor)
  8. (2024) Executive Committee, National, (Resource Person)
  9. (2023) Msd Gyne Cancer Expert Input Forum, National, (Expert Advisor)
  10. (2023) Roche Advisory Board Meeting On Hepatocellular Carcinoma, National, (Expert Advisor)
  11. (2023) Msd Gastric-Gej Ca Eif, National, (Expert Advisor)
  12. (2023) Asco Asia Pacific Regional Council Member, International, (Expert Advisor)
  13. (2022) Head & Neck Cancer Meet The Expert, National, (Expert Advisor)
  14. (2022) Head and Neck Cancer Global Virtual Advisory Board, July 2022, International, (Expert Advisor)
  15. (2022) Pakar Kunjungan Bagi Perkhidmatan Onkologi Klinikal Husm, National, (Visiting clinical specialists)
  16. (2021) Expert for The Pan-Asia Adapted Esmo Clinical Practice Guidelines On Squamous Head Neck Cancer, International, (Expert Advisor)
  17. (2020) Expert Input FORUM, MSD MALAYSIA SDN BHD, National
  18. (2020) VISITING CONSULTANT FOR CLINICAL ONCOLOGY HUSM, KUBANG KERIAN , HUSM KUBANG KERIAN & UNIT ONCOLOGY CLINICAL, FACULTY OF MEDICINE UM, National
  19. (2020) Asian multicenter prospective study of circulating TumoR DNASequencINg (A-TRAIN study), National Cancer Center Hospital, Tokyo, Japan & Clinical Oncology Unit, Faculty of Medicine, UM, International
  20. (2020) Bone Health Workshop 2020, Amgen (M) Sdn Bhd, National
  21. (2020) Re-Imagining Healthcare Hackathon, Roche Malaysia Sdn Bhd
  22. (2019) Bone Health Workshop 2019, Amgen (M) Sdn Bhd, Clinical Oncology Unit, Faculty of Medicine, National
  23. (2019) Masterclass in Systemic Therapy 2019, Malaysian Oncological Society, Unit Onkologi Klinikal, Fakulti Perubatan UM, National
  24. (2019) JAWATANKUASA CLINICAL ONCOLOGY SPECIALTY (COSCO), Malaysian Oncological Society, Ministry of Health, Clinical Oncology Unit, Faculty of Medicine UM, National
  25. (2012) ESMO ASIA CME PARTNER CENTRE: COLORECTAL CANCER PROGRAM, EUROPEAN SOCIETY OF MEDICAL ONCOLOGY, International
Contribution to event
  1. (2023) Panelist for Bms Educational Io Patient Case (Eclipse) Meeting, International, (Panelist/Moderator)
  2. (2022) Speaker - Immune-Checkpoint-Inhibitors for Biliary Tract Cancer in The Era of Precision Medicine, National, (Panelist/Moderator)
  3. (2022) Updates On Systemic Therapy of Relapsed/Metastatic Head and Neck Cancer, University, (Panelist/Moderator)
  4. (2022) Committee Member, National, (Event Organiser)
  5. (2022) Scientific Chairperson, Moderator, National, (Event Organiser)
  6. (2022) Invites Speaker and Panelist, International, (Panelist/Moderator)
  7. (2021) Optimizing Initiation Timing and Initial Dosing in The Management of Thyroid Cancer: Clinical Decision from New Data, International, (Panelist/Moderator)
  8. (2021) Msd Symposium Ashno 2021 - Chairperson & Moderator, International, (Panelist/Moderator)
  9. (2021) Exco Members of Ashno Congress 2021, International, (Event Organiser)
  10. (2021) Unlocking a New Era in Hcc Management: Multidisciplinary Approach to Hcc - as Expert Panel, National, (Panelist/Moderator)
  11. (2021) Expert Meeting Differentiated Thyroid Carcinoma (Dtc) - as Chairperson and Moderator, National, (Panelist/Moderator)
  12. (2021) As Chairperson, Moderator, and Panelist for The Hnscc Keynote 048 Virtual Launch 2021, National, (Panelist/Moderator)
Media appearance
  1. (2022) Invited Panel, National, (Interview)
  2. (2022) Article Contributor On Cancer in My Community: Addressing Increasing Cancer Cases in Malaysia, International, (Panelist/Moderator)

SUPERVISION

Postgraduate Student
PhD/ Doctoral
  1. (2011) NUTRITIONAL SUPPLEMENTATION IN COLORECTAL CANCER PATIENTS AFTER CHEMOTHERAPY: RANDOMISED CONTROL TRIAL., BABAK GOLKHALKHALI
Master
  1. (2024) Views, Barriers and Facilitators of Healthcare Professionals and Patients Regarding Trastuzumab Biosimilar use in the Treatment of Her2+ Breast Cancer, WONG YIN YEN
  2. (2020) Treatment Outcome of Esophageal Carcinoma in UMMC, Tang Seen Paul
  3. (2020) Treatment Outcome of Epithelial Ovarian Carcinoma in UMMC, Sangeeta Vahnalingam
  4. (2020) The prevalence of p16 positivity in HN SCC, Izzati Binti Wan Maharuddin
  5. (2020) Skin toxicity associated with radiotherapy: Benefits of using Mepitel film versus conventional skin care on radiation-induced skin reactions in head and neck cancer patients., Tang Shir Ley
  6. (2020) Role of Gamma knife in multiple brain metastases., Audi Adawiah Sulaiman Shah
  7. (2020) Neoadjuvant chemotherapy in SCCHN cancer in UMMC/IKN, Nor Hayati Binti Hashim
  8. (2020) Gut microbiomes and the response to chemotherapy in metastatic colorectal cancer, Nurul Atiqah Binti Mat Nasukhat
  9. (2020) Chemotherapy in early breast cancer: anthracycline versus taxane base in HUKM and HKL., Puvaneswarry A/P Miundy
  10. (2019) Views, barries and facilitators of Healthcare Professionals and Patiets/carers regarding trastuzumab biosimilar use in the treatment of HER2+ breast cancer in Malaysia., Wong Yin Yen
  11. (2016) TREATMENT OUTCOME OF CERVICAL CARCINOMA PATIENTS TREATED WITH POST-OPERATIVE CONCURRENT CHEMORADIATION AT UNIVERSITY MALAYA MEDICAL CENTER, MALAYSIA FROM YEAR 2000-2009, Santhi Nadarajan
  12. (2016) CHEMOTHERAPY INDUCED NAUSEA AND VOMITING AND QUALITY OF LIFE AMONG PATIENTS TREATED WITH MODERATE AND HIGHLY EMETOGENIC CHEMOTHERAPY, Eznal Ezwandi Mohd Mahidin
  13. (2015) The Effect of Mouthwash and Ice Chips on the Mucositis Among Colorectal Cancer Patient Undergoing Chemotherapy, Ros Idayu Binti Mat Nawi
  14. (2013) Survival Of Patients With Colon Cancer Stage 2 & 3 in University of Malaya Medical Centre, ASTRID SINARTI BINTI HASSAN
  15. (2013) CLINICAL SUPERVISION, TAN LI MEI
  16. (2013) CLINICAL SUPERVISION, MUTHUKKUMARAN A/L THIAGARAJAN
  17. (2013) CLINICAL SUPERVISION, LIM CHUN SEN
  18. (2013) Clinical Supervision, Dr Noor Zafifah Binti Zakaria
  19. (2013) Clinical Supervision, Dr Choong Swee Hsia
  20. (2013) CLINICAL SUPERVISION, ARNIL GEOGRE SIRIMANNE
  21. (2011) CLINICAL SUPERVISION, Tan Chih Kiang
  22. (2011) CLINICAL SUPERVISION, SUHANA YUSAK
  23. (2011) CLINICAL SUPERVISION, Natasha Mohd Hashim
  24. (2011) CLINICAL SUPERVISION, Marfuah Nik Eezamuddeen
  25. (2011) CLINICAL SUPERVISION, Astrid Sinarti Hassan

TEACHING

Master
  1. (2011) MQGQ6115 - Radiobiology and Radiation Protection
Bachelor
  1. (2020) UMMP -
  2. (2012) MTEJ3190 - Clinical Teaching Practicum
  3. (2011) MTEJ3102 - Medical Sciences 1

SOCIAL RESPONSIBILITY ACTIVITIES

  • Fitness Marathon 240 Mins Non Stop Collaboration With Asia Pacific University, Department of Dietatic Ummc, Department of Sport Medicine, Ummc., (04 Apr 2020 - 04 Apr 2020)
  • Thyroid Cancer Seminar, (07 Mar 2020 - 07 Mar 2020)
  • Oncology Bone Health Workshop, (07 Mar 2020 - 07 Mar 2020)
  • National Orthopaedic Oncology Revision Course 2020, (18 Jan 2020 - 18 Jan 2020)
  • Seminar The New Era of Prcision Medicine by Mma & Alps Global Holdings, (14 Dec 2019 - 14 Dec 2019)
  • Public Talk to Johnson & Johnson's Staff for Cancer Awareness Event, (08 Mar 2013 - 08 Mar 2013)
  • Esmo Asia Cme Partner Centre: Colorectal Cancer Program, (20 Oct 2012 - 20 Oct 2012)

COURSE ATTENDED

Internal / External Course
CONFERENCE
  1. ESTRO 2023 VIENNA, Vienna Austria (11 May 2023 - 17 May 2023)
  2. ASCO REGIONAL COUNCIL MEETING AND ASCO BREAKTHROUGH 2023, Intercontinental Hotel Yokohama (01 Aug 2023 - 06 Aug 2023)
  3. MK4280A-010 F2F EMEA/APAC INVESTIGATOR MEETING, Madrid Spain (11 Sep 2023 - 14 Sep 2023)
  4. E PAN-ASIA ADAPTED ESMO CLINICAL PRACTICE GUIDELINES ON GASTRIC CANCER, Tokyo (25 Aug 2023 - 27 Aug 2023)
  5. MK7902-014 (LEAP014) RECRUITMENT RETENTION INVESTIGATOR MEETING, Hilton London Metropole in London, England, UK. (24 Sep 2023 - 26 Sep 2023)